Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Attention Deficit Hyperactivity Disorder (ADHD): later-stage trial registry
5 of 19 indexed Attention Deficit Hyperactivity Disorder (ADHD) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 5 currently recruiting · #902 of 28,707 conditions by registered trial count
Attention Deficit Hyperactivity Disorder (ADHD): 19 US clinical trials tracked, 5 recruiting.
Attention Deficit Hyperactivity Disorder (ADHD) is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Shire, running 3 of these trials.
Enrollment posture brief
Registry condition attention-deficit-hyperactivity-disorder-adhd
OPEN 5 | RECR 26% | LATE 10 | EARLY 2 | RANK #902 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Concussion, Mild (26% recruiting · 19 trials)
Attention Deficit Hyperactivity Disorder (ADHD) lists 5 open slots (26% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Attention Deficit Hyperactivity Disorder (ADHD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Attention Deficit Hyperactivity Disorder (ADHD) is recruiting below its size-band peers.
5 of 19 indexed trials (26.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Attention Deficit Hyperactivity Disorder (ADHD) research.
Shire accounts for 3 of 19 trials (15.8%). 16 distinct sponsors appear on at least one study for this condition label.
-
Typical Attention Deficit Hyperactivity Disorder (ADHD) enrolment sits around 96 participants.
Median target enrolment is 96 among the 19 trials that report a genuine target (sentinel values excluded). 10 of those (52.6%) plan for fewer than 100 participants.
-
Attention Deficit Hyperactivity Disorder (ADHD) research is mostly interventional.
18 interventional and 1 observational studies make up this index (94.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
Improving ADHD Teen Driving - Virtual Reality
Children's Hospital Medical Center, Cincinnati
NCT06960980
Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Heterogeneity in ADHD
Hugo W. Moser Research Institute at Kennedy Krieger
NCT06810180
The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
Gagan Joshi
NCT06853665
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
St. Jude Children's Research Hospital
NCT07226219
L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD
Texas Tech University Health Sciences Center
NCT07189442
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
Supernus Pharmaceuticals
NCT02618408
Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD
Shire
NCT00500071
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
Shire
NCT02604407
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Shire
NCT02466425
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
Novartis Pharmaceuticals
NCT00776009
Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program)
Weill Medical College of Cornell University
NCT02574273
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
Supernus Pharmaceuticals
NCT04786990
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Sumitomo Pharma America
NCT03231800
PRC-063 in an ADULT Workplace Environment
Rhodes Pharmaceuticals, L.P.
NCT02225639
Organizational Skill Training (OST) in Schools
NYU Langone Health
NCT02663986
Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder
Wake Forest University Health Sciences
NCT01430767
Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
Aevi Genomic Medicine, LLC, a Cerecor company
NCT02286817
Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
Massachusetts General Hospital
NCT00753012
12 Month Open Extension of TNS for ADHD.
James McGough
NCT03888391
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 5 |
| Phase 4 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Attention Deficit Hyperactivity Disorder (ADHD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Attention Deficit Hyperactivity Disorder (ADHD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Attention Deficit Hyperactivity Disorder (ADHD) page
19 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Attention Deficit Hyperactivity Disorder (ADHD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Shire sponsors the most Attention Deficit Hyperactivity Disorder (ADHD) trials on record, review their full trial history before evaluating a specific study. See Shire's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Attention Deficit Hyperactivity Disorder (ADHD) condition card totals 19 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.